HBM Holdings Limited (HKG:2142)

Market Cap	12.36B +117.9%
Revenue (ttm)	1.23B +314.6%
Net Income	710.88M +3,187.7%
EPS	0.86 +2,942.0%
Shares Out	835.74M
PE Ratio	17.27
Forward PE	27.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,515,000
Average Volume	4,765,301
Open	14.79
Previous Close	14.79
Day's Range	14.48 - 14.79
52-Week Range	6.90 - 17.98
Beta	1.49
RSI	65.84
Earnings Date	Mar 30, 2026

About HBM Holdings

HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds and inhibits the neonatal fragment crystallizable receptor for tr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 272
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2142

Financial Performance

In 2025, HBM Holdings's revenue was $157.98 million, an increase of 314.63% compared to the previous year's $38.10 million. Earnings were $91.33 million, an increase of 3187.72%.

Financial numbers in USD